CLL is the most common leukemia in Western countries. The clinical course of CLL is highly heterogeneous. During the last decade, the treatment options for CLL has developed from maximum tolerated chemoimmunotherapy to targeted therapies. This has revealed the unmet need to systematically consider disease features, patient characteristics including comorbidities, logistics and patients’ preferences alike to provide the optimal individualized treatment for patients. Thus, a more comprehensive data-driven approach to immune complications, treatment outcomes, and disease outcomes among patients with hematological cancer is warranted. 

By capturing paraclinical, clinical and demographic data along with genetic and functional characterization of primary hematological cancer cells in our data laboratory, we assemble multidimensional data on patients with CLL through the Danish Lymphoid Cancer Research (DALY-CARE) data resource. With a unique three-pronged setup combining translational re-search, clinical trials and registry based "real world evidence", we explore patterns predictive of treatment outcome, infectious complications and disease outcome upon specific treatment. 

​Group leader

​​Carsten Utoft Niemann
Professor at University of Copenhagen, Chief Physician at Rigshospitalet, MD, PhD, Principal Investigator at Danish Cancer Society, Head of CLL Laboratory, Board member of Nordic CLL Study Group

Mail: carsten.utoft.niemann@regionh.dk

See list of publications​​

​